Finasteride blocks one DHT-making enzyme; dutasteride blocks both. We break down the history, the binding affinities, the scalp enzyme map, head-to-head efficacy, and the lowest and standard doses of each. Educational only, not medical advice.
One blocks the proven enzyme. The other blocks both, harder. The history, the biology, and what the data actually shows.
Finasteride and dutasteride are the two oral medicines that lower DHT, the hormone behind male pattern baldness. They are often described as "the weaker one and the stronger one," which is true but skips the interesting part. The real difference is which enzyme each one blocks, and that single fact explains everything downstream: the depth of DHT suppression, the head-to-head efficacy edge, the longer commitment, and the difference in approval status.
This is an educational comparison, not medical advice. Both are prescription medicines, dutasteride for hair is off-label in the U.S., and the right choice is a decision to make with a clinician.
| Finasteride (1 mg) | Dutasteride (0.5 mg) | |
|---|---|---|
| What it blocks | One DHT-making enzyme (type 2) | Both enzymes (type 1 and type 2) |
| Serum DHT drop | ~70% | ~95% |
| Who it suits | First-timers, most early-stage users | Finasteride non-responders, faster or more aggressive loss |
| Onset | 3 to 6 months, keeps improving for years | Often a little quicker or stronger |
| Clears your system | Hours | Weeks (much longer half-life) |
| U.S. approval for hair | Yes (since 1997) | No, off-label (approved for hair in South Korea, Japan, Taiwan) |
Finasteride exists because of a natural experiment. In the 1970s, researchers studying a cluster of genetically male children in the Dominican Republic found that they were born almost unable to make DHT. They grew up with small prostates, little body hair, and notably, they did not develop male pattern baldness or acne. The cause was a missing copy of one enzyme: 5-alpha-reductase type 2 (first described by Imperato-McGinley 1974; molecularly characterized in Thigpen 1993).
Merck read that as a blueprint: block type 2 5-alpha-reductase and you should shrink the prostate, and perhaps protect the hair. That became finasteride, approved as Proscar (5 mg) for an enlarged prostate in 1992 and as Propecia (1 mg) for hair in 1997. It was the first drug ever built specifically to lower DHT.
Dutasteride arrived a decade later. It was designed to inhibit both forms of the enzyme for deeper DHT suppression, and was approved as Avodart (0.5 mg) for an enlarged prostate in 2002. For hair it took a separate path: approved for androgenetic alopecia in South Korea and later Japan and Taiwan, but never FDA-approved for hair loss in the U.S.
There are actually three forms of 5-alpha-reductase, encoded by separate genes, but only two are relevant to hair. Type 1 predominates in skin and oil (sebaceous) glands. Type 2 predominates in the prostate and genital skin, and within the hair follicle it is concentrated in the dermal papilla, the cluster of cells that actually tells a follicle to grow or shrink (Asada 2001). (The third, type 3 or SRD5A3, is mainly a glycosylation enzyme; its best-documented androgen role is in castration-resistant prostate cancer, and it has no established role in androgenetic alopecia, so the hair story stays on type 1 and type 2.)
Here is the counterintuitive part. When Sawaya and Price measured both enzymes directly in plucked scalp follicles, type 1 was the more abundant one, running about four to five times higher than type 2.
Type 1 is the abundant one in the follicle; type 2 is the one drugs and genetics tie to balding.
5α-reductase activity, men, frontal follicles · Sawaya & Price 1997
IC50, lower = stronger inhibition · Azzouni 2012
| Type 1 | Type 2 | |
|---|---|---|
| Finasteride | 360 nM | 69 nM |
| Dutasteride | 7 nM | 6 nM |
Yet type 2 is the form we can actually prove is involved in balding: the men born without it keep their hair (Imperato-McGinley 1974), and finasteride, which blocks essentially only type 2, clearly regrows hair. Abundance is not the same as proof. Type 1 is the more abundant one in your scalp, but most of it sits in your oil glands, not the dermal papilla where the follicle actually shrinks. When scalp is stained for the type 1 protein, it lights up the sebaceous glands and leaves the hair follicle dark; type 2 is the form that stains inside the follicle (Bayne 1999). An older enzyme-activity assay on plucked follicles did detect some type 1 in the outer root sheath (Sawaya 1997), so the two methods disagree on whether any type 1 reaches the follicle at all, but both place it away from the dermal papilla. So the abundant enzyme is largely in the wrong compartment to drive miniaturization; type 1 is simply the one we have no way to prove innocent.
An important and underappreciated honesty note: the evidence here is asymmetric. There is no human "born without type 1" to compare against. No genetic deficiency of type 1 has ever been described, then or since (Thigpen 1993); the classic 5-alpha-reductase deficiency is specifically a type 2 mutation, and the type 1 gene is normal in those men. So we have never been able to run the type 1 experiment. That means "type 2 is the one tied to balding" really means "type 2 is the one we can prove," not "type 1 does not matter."
In fact, type 1 probably does matter. Finasteride caps out around a 70% drop in blood DHT precisely because type 2 makes only about 80% of circulating DHT (Gisleskog 1998); type 1 makes the rest, and finasteride barely touches it. So type 1 contributes a real share of DHT, and it is the more abundant 5-alpha-reductase in the scalp overall. How much that type-1 DHT specifically drives scalp balding is genuinely unresolved, which is part of why blocking both enzymes, as dutasteride does, is worth studying.
The cleanest way to see the difference between the drugs is their binding affinity (IC50, the concentration that inhibits half the enzyme; lower is more potent). The widely cited values, tabulated together in Azzouni 2012 (finasteride from Tian 1994; dutasteride from Bramson 1997), are:
| Enzyme | Finasteride IC50 | Dutasteride IC50 |
|---|---|---|
| Type 1 | 360 nM | 7 nM |
| Type 2 | 69 nM | 6 nM |
A caveat worth stating: in-vitro IC50 values for 5-alpha-reductase vary enormously by assay (enzyme source, substrate, pH), so treat the exact numbers as approximate. Two facts hold up across assays (Azzouni 2012):
That second point matters for interpreting the comparison: dutasteride's advantage is not only that it adds type 1. It also blocks type 2 more completely. No clinical trial can cleanly separate "deeper type 2 block" from "added type 1 block," so the honest takeaway is simply that dutasteride lowers DHT more, by hitting both enzymes harder.
The clearest comparison is a single head-to-head study (Clark 2004): dutasteride 0.5 mg reduced serum DHT by 94.7%, versus 70.8% for finasteride 5 mg; dutasteride 5 mg reached 98.4%. The same pattern holds in the scalp itself, where Olsen 2006 found dutasteride reduced scalp DHT in a dose-dependent way, about 51% at 0.5 mg and 79% at 2.5 mg, versus about 41% for finasteride 5 mg.
Deeper DHT suppression translates into more hair in direct comparisons, though the edge is modest and the trials are not large.
The honest read: dutasteride is consistently at least as good as, and usually modestly better than, finasteride over six months. None of these are long, large, or independent enough to pin the size of the gap precisely, and head-to-head safety over years is not well characterized.
There are two useful "minimums" for each drug: the lowest dose with robust, proven efficacy, and the floor, the lowest dose that has shown any measurable regrowth at all. They are not the same.
| Drug and route | Lowest dose with any shown growth | Standard / optimal dose |
|---|---|---|
| Finasteride, oral | 0.01 mg/day (Roberts 1999, lowest arm) | 1 mg/day |
| Finasteride, topical | 0.005% (Mazzarella 1997) | ~0.25% (compounded) |
| Dutasteride, oral | 0.02 mg/day (Gubelin Harcha 2014, lowest arm) | 0.5 mg/day |
| Dutasteride, topical | ~0.01% with microneedling (Ding 2024 review) | 0.05% (Panuganti 2025) |
For finasteride, DHT suppression saturates remarkably early: serum DHT falls 49.5% at 0.05 mg, 68.6% at 0.2 mg, 71.4% at 1 mg, and 72.2% at 5 mg (Drake 1999). Hair-count benefit keeps climbing a little past that, so Roberts 1999 called 1 mg the optimal oral dose, even though the lowest 0.01 mg arm still produced a modest gain over placebo.
For dutasteride, 0.5 mg/day is the proven, approved dose, the only one to reach statistical significance for hair count (Gubelin Harcha 2014; Eun 2010). Lower doses tested down to 0.02 mg still rose dose-dependently, just without reaching the significance bar. One framing that helps: a 0.5 mg dose of dutasteride suppresses DHT more than even a 5 mg dose of finasteride, because it is blocking a second enzyme, not simply more of the same one. Note that "floor" doses mean the lowest dose where a study reported any regrowth, not a dose anyone recommends.
Both drugs share the same class profile: a minority of men report sexual side effects (reduced libido, erectile or ejaculatory changes) and mood changes. Reported sexual adverse-event rates are broadly comparable between the two within trials, though dutasteride suppresses DHT more deeply (Lee 2018).
The most practical difference is pharmacokinetics. Finasteride has a half-life of around 6 hours, so it clears within a day or two of stopping. Dutasteride has a terminal half-life of roughly 5 weeks, so it lingers for months. If side effects appear, they take much longer to wash out, and men on dutasteride are advised to defer blood donation for 6 months after the last dose. Most men tolerate either drug; the decision is individual and clinician-guided.
A growing strategy with both drugs is to apply them to the scalp instead of taking them orally, aiming to lower DHT at the follicle while keeping systemic DHT suppression low, because most of a topically applied dose never reaches the bloodstream. For dutasteride, a 2025 randomized trial reported a topical dutasteride solution beat oral finasteride on hair count while serum DHT and testosterone stayed essentially flat (Panuganti 2025). The evidence is still thin, and like oral dutasteride for hair, topical dutasteride is a compounded, off-label preparation in the U.S.
| Scenario | Common approach (discuss with your clinician) |
|---|---|
| First-time oral therapy, early or moderate loss | Start with finasteride 1 mg |
| Minimal response after about 12 months of finasteride | Consider switching to dutasteride 0.5 mg |
| Rapid, aggressive loss at temples and vertex | Some clinicians consider dutasteride earlier, with oversight |
| Trying to conceive in the next 6 months | Discuss timing; both are systemic and dutasteride is long-acting |
Finasteride blocks the one enzyme most clearly tied to balding, type 2, which is exactly why it works, and it is the established first-line, FDA-approved option. Dutasteride blocks both enzymes and blocks type 2 harder, so it suppresses DHT more deeply and grows modestly more hair head-to-head, at the cost of a much longer half-life and off-label status in the U.S. Neither is a cure, and the right call depends on your goals, your response, and a conversation with a clinician.
This article is for educational purposes only and is not medical advice. Finasteride and dutasteride are prescription medicines; dutasteride is not FDA-approved for hair loss in the U.S. and is used off-label. Discuss risks and benefits with a qualified clinician before starting, changing, or stopping any treatment.
Finasteride blocks one DHT-making enzyme; dutasteride blocks both. We break down the history, the binding affinities, the scalp enzyme map, head-to-head efficacy, and the lowest and standard doses of each. Educational only, not medical advice.
One blocks the proven enzyme. The other blocks both, harder. The history, the biology, and what the data actually shows.
Finasteride and dutasteride are the two oral medicines that lower DHT, the hormone behind male pattern baldness. They are often described as "the weaker one and the stronger one," which is true but skips the interesting part. The real difference is which enzyme each one blocks, and that single fact explains everything downstream: the depth of DHT suppression, the head-to-head efficacy edge, the longer commitment, and the difference in approval status.
This is an educational comparison, not medical advice. Both are prescription medicines, dutasteride for hair is off-label in the U.S., and the right choice is a decision to make with a clinician.
| Finasteride (1 mg) | Dutasteride (0.5 mg) | |
|---|---|---|
| What it blocks | One DHT-making enzyme (type 2) | Both enzymes (type 1 and type 2) |
| Serum DHT drop | ~70% | ~95% |
| Who it suits | First-timers, most early-stage users | Finasteride non-responders, faster or more aggressive loss |
| Onset | 3 to 6 months, keeps improving for years | Often a little quicker or stronger |
| Clears your system | Hours | Weeks (much longer half-life) |
| U.S. approval for hair | Yes (since 1997) | No, off-label (approved for hair in South Korea, Japan, Taiwan) |
Finasteride exists because of a natural experiment. In the 1970s, researchers studying a cluster of genetically male children in the Dominican Republic found that they were born almost unable to make DHT. They grew up with small prostates, little body hair, and notably, they did not develop male pattern baldness or acne. The cause was a missing copy of one enzyme: 5-alpha-reductase type 2 (first described by Imperato-McGinley 1974; molecularly characterized in Thigpen 1993).
Merck read that as a blueprint: block type 2 5-alpha-reductase and you should shrink the prostate, and perhaps protect the hair. That became finasteride, approved as Proscar (5 mg) for an enlarged prostate in 1992 and as Propecia (1 mg) for hair in 1997. It was the first drug ever built specifically to lower DHT.
Dutasteride arrived a decade later. It was designed to inhibit both forms of the enzyme for deeper DHT suppression, and was approved as Avodart (0.5 mg) for an enlarged prostate in 2002. For hair it took a separate path: approved for androgenetic alopecia in South Korea and later Japan and Taiwan, but never FDA-approved for hair loss in the U.S.
There are actually three forms of 5-alpha-reductase, encoded by separate genes, but only two are relevant to hair. Type 1 predominates in skin and oil (sebaceous) glands. Type 2 predominates in the prostate and genital skin, and within the hair follicle it is concentrated in the dermal papilla, the cluster of cells that actually tells a follicle to grow or shrink (Asada 2001). (The third, type 3 or SRD5A3, is mainly a glycosylation enzyme; its best-documented androgen role is in castration-resistant prostate cancer, and it has no established role in androgenetic alopecia, so the hair story stays on type 1 and type 2.)
Here is the counterintuitive part. When Sawaya and Price measured both enzymes directly in plucked scalp follicles, type 1 was the more abundant one, running about four to five times higher than type 2.
Type 1 is the abundant one in the follicle; type 2 is the one drugs and genetics tie to balding.
5α-reductase activity, men, frontal follicles · Sawaya & Price 1997
IC50, lower = stronger inhibition · Azzouni 2012
| Type 1 | Type 2 | |
|---|---|---|
| Finasteride | 360 nM | 69 nM |
| Dutasteride | 7 nM | 6 nM |
Yet type 2 is the form we can actually prove is involved in balding: the men born without it keep their hair (Imperato-McGinley 1974), and finasteride, which blocks essentially only type 2, clearly regrows hair. Abundance is not the same as proof. Type 1 is the more abundant one in your scalp, but most of it sits in your oil glands, not the dermal papilla where the follicle actually shrinks. When scalp is stained for the type 1 protein, it lights up the sebaceous glands and leaves the hair follicle dark; type 2 is the form that stains inside the follicle (Bayne 1999). An older enzyme-activity assay on plucked follicles did detect some type 1 in the outer root sheath (Sawaya 1997), so the two methods disagree on whether any type 1 reaches the follicle at all, but both place it away from the dermal papilla. So the abundant enzyme is largely in the wrong compartment to drive miniaturization; type 1 is simply the one we have no way to prove innocent.
An important and underappreciated honesty note: the evidence here is asymmetric. There is no human "born without type 1" to compare against. No genetic deficiency of type 1 has ever been described, then or since (Thigpen 1993); the classic 5-alpha-reductase deficiency is specifically a type 2 mutation, and the type 1 gene is normal in those men. So we have never been able to run the type 1 experiment. That means "type 2 is the one tied to balding" really means "type 2 is the one we can prove," not "type 1 does not matter."
In fact, type 1 probably does matter. Finasteride caps out around a 70% drop in blood DHT precisely because type 2 makes only about 80% of circulating DHT (Gisleskog 1998); type 1 makes the rest, and finasteride barely touches it. So type 1 contributes a real share of DHT, and it is the more abundant 5-alpha-reductase in the scalp overall. How much that type-1 DHT specifically drives scalp balding is genuinely unresolved, which is part of why blocking both enzymes, as dutasteride does, is worth studying.
The cleanest way to see the difference between the drugs is their binding affinity (IC50, the concentration that inhibits half the enzyme; lower is more potent). The widely cited values, tabulated together in Azzouni 2012 (finasteride from Tian 1994; dutasteride from Bramson 1997), are:
| Enzyme | Finasteride IC50 | Dutasteride IC50 |
|---|---|---|
| Type 1 | 360 nM | 7 nM |
| Type 2 | 69 nM | 6 nM |
A caveat worth stating: in-vitro IC50 values for 5-alpha-reductase vary enormously by assay (enzyme source, substrate, pH), so treat the exact numbers as approximate. Two facts hold up across assays (Azzouni 2012):
That second point matters for interpreting the comparison: dutasteride's advantage is not only that it adds type 1. It also blocks type 2 more completely. No clinical trial can cleanly separate "deeper type 2 block" from "added type 1 block," so the honest takeaway is simply that dutasteride lowers DHT more, by hitting both enzymes harder.
The clearest comparison is a single head-to-head study (Clark 2004): dutasteride 0.5 mg reduced serum DHT by 94.7%, versus 70.8% for finasteride 5 mg; dutasteride 5 mg reached 98.4%. The same pattern holds in the scalp itself, where Olsen 2006 found dutasteride reduced scalp DHT in a dose-dependent way, about 51% at 0.5 mg and 79% at 2.5 mg, versus about 41% for finasteride 5 mg.
Deeper DHT suppression translates into more hair in direct comparisons, though the edge is modest and the trials are not large.
The honest read: dutasteride is consistently at least as good as, and usually modestly better than, finasteride over six months. None of these are long, large, or independent enough to pin the size of the gap precisely, and head-to-head safety over years is not well characterized.
There are two useful "minimums" for each drug: the lowest dose with robust, proven efficacy, and the floor, the lowest dose that has shown any measurable regrowth at all. They are not the same.
| Drug and route | Lowest dose with any shown growth | Standard / optimal dose |
|---|---|---|
| Finasteride, oral | 0.01 mg/day (Roberts 1999, lowest arm) | 1 mg/day |
| Finasteride, topical | 0.005% (Mazzarella 1997) | ~0.25% (compounded) |
| Dutasteride, oral | 0.02 mg/day (Gubelin Harcha 2014, lowest arm) | 0.5 mg/day |
| Dutasteride, topical | ~0.01% with microneedling (Ding 2024 review) | 0.05% (Panuganti 2025) |
For finasteride, DHT suppression saturates remarkably early: serum DHT falls 49.5% at 0.05 mg, 68.6% at 0.2 mg, 71.4% at 1 mg, and 72.2% at 5 mg (Drake 1999). Hair-count benefit keeps climbing a little past that, so Roberts 1999 called 1 mg the optimal oral dose, even though the lowest 0.01 mg arm still produced a modest gain over placebo.
For dutasteride, 0.5 mg/day is the proven, approved dose, the only one to reach statistical significance for hair count (Gubelin Harcha 2014; Eun 2010). Lower doses tested down to 0.02 mg still rose dose-dependently, just without reaching the significance bar. One framing that helps: a 0.5 mg dose of dutasteride suppresses DHT more than even a 5 mg dose of finasteride, because it is blocking a second enzyme, not simply more of the same one. Note that "floor" doses mean the lowest dose where a study reported any regrowth, not a dose anyone recommends.
Both drugs share the same class profile: a minority of men report sexual side effects (reduced libido, erectile or ejaculatory changes) and mood changes. Reported sexual adverse-event rates are broadly comparable between the two within trials, though dutasteride suppresses DHT more deeply (Lee 2018).
The most practical difference is pharmacokinetics. Finasteride has a half-life of around 6 hours, so it clears within a day or two of stopping. Dutasteride has a terminal half-life of roughly 5 weeks, so it lingers for months. If side effects appear, they take much longer to wash out, and men on dutasteride are advised to defer blood donation for 6 months after the last dose. Most men tolerate either drug; the decision is individual and clinician-guided.
A growing strategy with both drugs is to apply them to the scalp instead of taking them orally, aiming to lower DHT at the follicle while keeping systemic DHT suppression low, because most of a topically applied dose never reaches the bloodstream. For dutasteride, a 2025 randomized trial reported a topical dutasteride solution beat oral finasteride on hair count while serum DHT and testosterone stayed essentially flat (Panuganti 2025). The evidence is still thin, and like oral dutasteride for hair, topical dutasteride is a compounded, off-label preparation in the U.S.
| Scenario | Common approach (discuss with your clinician) |
|---|---|
| First-time oral therapy, early or moderate loss | Start with finasteride 1 mg |
| Minimal response after about 12 months of finasteride | Consider switching to dutasteride 0.5 mg |
| Rapid, aggressive loss at temples and vertex | Some clinicians consider dutasteride earlier, with oversight |
| Trying to conceive in the next 6 months | Discuss timing; both are systemic and dutasteride is long-acting |
Finasteride blocks the one enzyme most clearly tied to balding, type 2, which is exactly why it works, and it is the established first-line, FDA-approved option. Dutasteride blocks both enzymes and blocks type 2 harder, so it suppresses DHT more deeply and grows modestly more hair head-to-head, at the cost of a much longer half-life and off-label status in the U.S. Neither is a cure, and the right call depends on your goals, your response, and a conversation with a clinician.
This article is for educational purposes only and is not medical advice. Finasteride and dutasteride are prescription medicines; dutasteride is not FDA-approved for hair loss in the U.S. and is used off-label. Discuss risks and benefits with a qualified clinician before starting, changing, or stopping any treatment.